Recent News

• 04.22.2025 - Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
• 04.21.2025 - Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
• 03.10.2025 - Fourth Quarter 2024 Financial Results Earnings Call
• 03.10.2025 - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.05.2025 - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
• 02.11.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 02.11.2025 - Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
• 02.04.2025 - Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
• 02.04.2025 - Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Recent Filings

• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 8-K Current report
• 03.10.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership